Obidoxime API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Obidoxime | CAS No: 7683-36-5 | GMP-certified suppliers
A medication that serves as a cholinesterase reactivator for treating organophosphate poisoning by restoring enzyme function and counteracting cholinergic overstimulation.
Therapeutic categories
Product Snapshot
- Obidoxime is formulated as an injectable small molecule
- It is primarily utilized for the reversal of organophosphate poisoning
- The compound currently holds experimental approval status and is not yet authorized by major regulatory agencies such as the FDA or EMA
Clinical Overview
Obidoxime is primarily investigated as an antidote, specifically within the experimental category, and functions as a cholinesterase reactivator. Its pharmacological activity centers on the reactivation of acetylcholinesterase inhibited by organophosphorus compounds, an effect relevant in cases of poisoning by organophosphate nerve agents or pesticides. By reactivating acetylcholinesterase, obidoxime restores the enzyme’s ability to hydrolyze acetylcholine, thereby counteracting cholinergic overstimulation caused by enzyme inhibition.
Given its enzymatic target, obidoxime is classified among cholinergic agents and enzyme reactivators. The compound’s physicochemical profile includes its pyridine and pyridinium moieties, which contribute to its interaction with enzyme active sites. Despite its investigational status, obidoxime has been used in some clinical or toxicological contexts to mitigate organophosphate poisoning, often in combination with other therapeutics such as atropine.
Pharmacokinetic data are limited but typical considerations include its bioavailability, distribution, and ability to cross biological barriers relevant to nervous system exposure. Safety and toxicity data remain limited and are typically evaluated in experimental settings; known risks relate predominantly to its cholinergic activity and potential systemic effects during acute poisoning management.
From a sourcing perspective, procurement of obidoxime API requires attention to strict quality control due to its sensitive therapeutic application and experimental status. Compliance with Good Manufacturing Practices (GMP) and batch-to-batch consistency are critical to ensure efficacy and safety in clinical or research use. Analytical characterization should confirm the chemical identity, purity, and absence of degradation products or impurities that could impact safety.
Identification & chemistry
| Generic name | Obidoxime |
|---|---|
| Molecule type | Small molecule |
| CAS | 7683-36-5 |
| UNII | N6KNE1QA9O |
| DrugBank ID | DB13750 |
Formulation & handling
- Obidoxime is a small molecule with extremely low water solubility, indicating challenges for aqueous formulation and potential need for solubilizing agents. Its negative LogP value suggests hydrophilic properties, influencing absorption and distribution profiles. As a non-biologic dihydropyridine derivative, standard chemical stability and handling protocols apply without sensitivity to food effects reported.
Regulatory status
Obidoxime is a type of Antidotes, Deterrents, and Toxicologic Agents
Antidotes, Deterrents, and Toxicologic Agents are an important category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that play a critical role in healthcare and toxicology. These substances are designed to counteract the effects of poisons, toxins, and overdoses, thereby saving lives and preventing severe health consequences.
Antidotes are substances that neutralize the toxic effects of certain drugs, chemicals, or poisons. They work by either directly binding to the toxic substance or by blocking its harmful actions on the body. Antidotes are administered in emergency situations to quickly reverse the effects of poisoning and restore normal physiological functions.
Deterrents, on the other hand, are pharmaceutical agents used to discourage or prevent harmful behaviors, such as substance abuse. They are designed to make the ingestion or misuse of certain substances unpleasant or less desirable. Deterrents can be formulated to cause unpleasant side effects, such as nausea or vomiting, when a particular substance is consumed in excessive amounts.
Toxicologic agents encompass a broad range of pharmaceutical APIs used in toxicology studies and research. These substances are employed to investigate the toxicity, metabolism, and mechanisms of action of various chemicals and compounds. Toxicologic agents are vital for understanding the potential hazards and risks associated with certain substances, ensuring the safety of drugs, and developing effective treatments for poisoning cases.
In conclusion, Antidotes, Deterrents, and Toxicologic Agents are essential categories of pharmaceutical APIs that address poisoning emergencies, deter harmful behaviors, and enable toxicological research. Their development and availability are crucial for safeguarding public health, enhancing patient care, and advancing our understanding of toxicology.
